Acalabrutinib for adults with mantle cell lymphoma

Wojciech Jurczak, Monika Długosz-Danecka, Luhua Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. However, ibrutinib-related adverse events due to off-target inhibition of other kinases led to the development of more selective molecules with comparable efficacy and better safety profiles. Expert commentary: Acalabrutinib, a new BTK inhibitor, currently being evaluated in numerous clinical studies is approved by FDA in relapsing/refractory MCL. Its role will evolve over the next few years. Efficacy and good tolerability of acalabrutinib gives even greater opportunity for potential upfront use and new therapeutic combinations, including monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, bcl-2 (B-cell lymphoma-2) or IP3K (phosphoinositide 3-kinase) inhibitors.

Original languageEnglish (US)
Pages (from-to)179-187
Number of pages9
JournalExpert Review of Clinical Pharmacology
Volume12
Issue number3
DOIs
StatePublished - Mar 4 2019

Fingerprint

Mantle-Cell Lymphoma
Cell- and Tissue-Based Therapy
1-Phosphatidylinositol 4-Kinase
B-Cell Lymphoma
Therapeutic Uses
Phosphotransferases
Monoclonal Antibodies
Safety
acalabrutinib
Antibodies
Pharmaceutical Preparations
Agammaglobulinaemia tyrosine kinase
PCI 32765
Therapeutics

Keywords

  • Acalabrutinib
  • Bruton tyrosine kinase inhibitors
  • adverse events
  • mantle cell lymphoma

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Acalabrutinib for adults with mantle cell lymphoma. / Jurczak, Wojciech; Długosz-Danecka, Monika; Wang, Luhua.

In: Expert Review of Clinical Pharmacology, Vol. 12, No. 3, 04.03.2019, p. 179-187.

Research output: Contribution to journalArticle

Jurczak, Wojciech ; Długosz-Danecka, Monika ; Wang, Luhua. / Acalabrutinib for adults with mantle cell lymphoma. In: Expert Review of Clinical Pharmacology. 2019 ; Vol. 12, No. 3. pp. 179-187.
@article{9d1ebddeb8374fb8865e86548f1a9047,
title = "Acalabrutinib for adults with mantle cell lymphoma",
abstract = "Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. However, ibrutinib-related adverse events due to off-target inhibition of other kinases led to the development of more selective molecules with comparable efficacy and better safety profiles. Expert commentary: Acalabrutinib, a new BTK inhibitor, currently being evaluated in numerous clinical studies is approved by FDA in relapsing/refractory MCL. Its role will evolve over the next few years. Efficacy and good tolerability of acalabrutinib gives even greater opportunity for potential upfront use and new therapeutic combinations, including monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, bcl-2 (B-cell lymphoma-2) or IP3K (phosphoinositide 3-kinase) inhibitors.",
keywords = "Acalabrutinib, Bruton tyrosine kinase inhibitors, adverse events, mantle cell lymphoma",
author = "Wojciech Jurczak and Monika Długosz-Danecka and Luhua Wang",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/17512433.2019.1568868",
language = "English (US)",
volume = "12",
pages = "179--187",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Acalabrutinib for adults with mantle cell lymphoma

AU - Jurczak, Wojciech

AU - Długosz-Danecka, Monika

AU - Wang, Luhua

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. However, ibrutinib-related adverse events due to off-target inhibition of other kinases led to the development of more selective molecules with comparable efficacy and better safety profiles. Expert commentary: Acalabrutinib, a new BTK inhibitor, currently being evaluated in numerous clinical studies is approved by FDA in relapsing/refractory MCL. Its role will evolve over the next few years. Efficacy and good tolerability of acalabrutinib gives even greater opportunity for potential upfront use and new therapeutic combinations, including monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, bcl-2 (B-cell lymphoma-2) or IP3K (phosphoinositide 3-kinase) inhibitors.

AB - Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. However, ibrutinib-related adverse events due to off-target inhibition of other kinases led to the development of more selective molecules with comparable efficacy and better safety profiles. Expert commentary: Acalabrutinib, a new BTK inhibitor, currently being evaluated in numerous clinical studies is approved by FDA in relapsing/refractory MCL. Its role will evolve over the next few years. Efficacy and good tolerability of acalabrutinib gives even greater opportunity for potential upfront use and new therapeutic combinations, including monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, bcl-2 (B-cell lymphoma-2) or IP3K (phosphoinositide 3-kinase) inhibitors.

KW - Acalabrutinib

KW - Bruton tyrosine kinase inhibitors

KW - adverse events

KW - mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85060677647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060677647&partnerID=8YFLogxK

U2 - 10.1080/17512433.2019.1568868

DO - 10.1080/17512433.2019.1568868

M3 - Article

VL - 12

SP - 179

EP - 187

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -